Literature DB >> 34824200

Signaling pathways and intervention therapies in sepsis.

Yun-Yu Zhang1, Bo-Tao Ning2.   

Abstract

Sepsis is defined as life-threatening organ dysfunction caused by dysregulated host systemic inflammatory and immune response to infection. Over decades, advanced understanding of host-microorganism interaction has gradually unmasked the genuine nature of sepsis, guiding toward new definition and novel therapeutic approaches. Diverse clinical manifestations and outcomes among infectious patients have suggested the heterogeneity of immunopathology, while systemic inflammatory responses and deteriorating organ function observed in critically ill patients imply the extensively hyperactivated cascades by the host defense system. From focusing on microorganism pathogenicity, research interests have turned toward the molecular basis of host responses. Though progress has been made regarding recognition and management of clinical sepsis, incidence and mortality rate remain high. Furthermore, clinical trials of therapeutics have failed to obtain promising results. As far as we know, there was no systematic review addressing sepsis-related molecular signaling pathways and intervention therapy in literature. Increasing studies have succeeded to confirm novel functions of involved signaling pathways and comment on efficacy of intervention therapies amid sepsis. However, few of these studies attempt to elucidate the underlining mechanism in progression of sepsis, while other failed to integrate preliminary findings and describe in a broader view. This review focuses on the important signaling pathways, potential molecular mechanism, and pathway-associated therapy in sepsis. Host-derived molecules interacting with activated cells possess pivotal role for sepsis pathogenesis by dynamic regulation of signaling pathways. Cross-talk and functions of these molecules are also discussed in detail. Lastly, potential novel therapeutic strategies precisely targeting on signaling pathways and molecules are mentioned.
© 2021. The Author(s).

Entities:  

Mesh:

Year:  2021        PMID: 34824200      PMCID: PMC8613465          DOI: 10.1038/s41392-021-00816-9

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  476 in total

1.  Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.

Authors:  Gordon R Bernard; Bruno Francois; Jean-Paul Mira; Jean-Louis Vincent; R Phillip Dellinger; James A Russell; Steven P Larosa; Pierre-Francois Laterre; Mitchell M Levy; Wayne Dankner; Nicola Schmitt; Justin Lindemann; Xavier Wittebole
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

2.  Systemic infections mimicking thrombotic thrombocytopenic purpura.

Authors:  Kristina K Booth; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Am J Hematol       Date:  2011-09       Impact factor: 10.047

3.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis.

Authors:  S N Faust; M Levin; O B Harrison; R D Goldin; M S Lockhart; S Kondaveeti; Z Laszik; C T Esmon; R S Heyderman
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

4.  Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.

Authors:  M Poeze; A H Froon; G Ramsay; W A Buurman; J W Greve
Journal:  Shock       Date:  2000-10       Impact factor: 3.454

Review 5.  Necroptosis in development, inflammation and disease.

Authors:  Ricardo Weinlich; Andrew Oberst; Helen M Beere; Douglas R Green
Journal:  Nat Rev Mol Cell Biol       Date:  2016-12-21       Impact factor: 94.444

6.  STING and TRIF Contribute to Mouse Sepsis, Depending on Severity of the Disease Model.

Authors:  Erica L Heipertz; Jourdan Harper; Wendy E Walker
Journal:  Shock       Date:  2017-05       Impact factor: 3.454

7.  Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells.

Authors:  Jeremy Bregeon; Gervaise Loirand; Pierre Pacaud; Malvyne Rolli-Derkinderen
Journal:  Am J Physiol Cell Physiol       Date:  2009-08-19       Impact factor: 4.249

Review 8.  DAMP and DIC: The role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC.

Authors:  Patricia C Liaw; Takashi Ito; Toshiaki Iba; Jecko Thachil; Sacha Zeerleder
Journal:  Blood Rev       Date:  2015-12-31       Impact factor: 8.250

9.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Authors:  C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

10.  Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.

Authors:  Shaun Spence; Michelle K Greene; François Fay; Emily Hams; Sean P Saunders; Umar Hamid; Marianne Fitzgerald; Jonathan Beck; Baljinder K Bains; Peter Smyth; Efrosyni Themistou; Donna M Small; Daniela Schmid; Cecilia M O'Kane; Denise C Fitzgerald; Sharif M Abdelghany; James A Johnston; Padraic G Fallon; James F Burrows; Daniel F McAuley; Adrien Kissenpfennig; Christopher J Scott
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

View more
  3 in total

1.  Association between glucose-to-lymphocyte ratio and in-hospital mortality in intensive care patients with sepsis: A retrospective observational study based on Medical Information Mart for Intensive Care IV.

Authors:  Shaoyan Cai; Qinjia Wang; Chuzhou Ma; Junheng Chen; Yang Wei; Lei Zhang; Zengqiang Fang; Liangjie Zheng; Chunming Guo
Journal:  Front Med (Lausanne)       Date:  2022-08-24

Review 2.  Nanodrugs alleviate acute kidney injury: Manipulate RONS at kidney.

Authors:  Qiaohui Chen; Yayun Nan; Yuqi Yang; Zuoxiu Xiao; Min Liu; Jia Huang; Yuting Xiang; Xingyu Long; Tianjiao Zhao; Xiaoyuan Wang; Qiong Huang; Kelong Ai
Journal:  Bioact Mater       Date:  2022-09-29

3.  Application of oXiris-continuous hemofiltration adsorption in patients with sepsis and septic shock: A single-centre experience in China.

Authors:  Yanyan Zhou; Chenfang Wu; Lin Ouyang; Ying Peng; Dingming Zhong; Xiaohong Xiang; Jinxiu Li
Journal:  Front Public Health       Date:  2022-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.